{
  "id": "5880b073c872c95565000003",
  "type": "factoid",
  "question": "Andexanet Alfa is an antidote of which clotting factor inhibitors?",
  "ideal_answer": "Andexanet alfa is a specific reversal agent for Factor Xa inhibitors.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26449414",
    "http://www.ncbi.nlm.nih.gov/pubmed/27082776",
    "http://www.ncbi.nlm.nih.gov/pubmed/27147456",
    "http://www.ncbi.nlm.nih.gov/pubmed/27575436",
    "http://www.ncbi.nlm.nih.gov/pubmed/25516695",
    "http://www.ncbi.nlm.nih.gov/pubmed/25816811",
    "http://www.ncbi.nlm.nih.gov/pubmed/27913536",
    "http://www.ncbi.nlm.nih.gov/pubmed/26559317",
    "http://www.ncbi.nlm.nih.gov/pubmed/25494843",
    "http://www.ncbi.nlm.nih.gov/pubmed/27789605",
    "http://www.ncbi.nlm.nih.gov/pubmed/27659071",
    "http://www.ncbi.nlm.nih.gov/pubmed/25431993",
    "http://www.ncbi.nlm.nih.gov/pubmed/26069913",
    "http://www.ncbi.nlm.nih.gov/pubmed/27697443",
    "http://www.ncbi.nlm.nih.gov/pubmed/27399455",
    "http://www.ncbi.nlm.nih.gov/pubmed/26627486",
    "http://www.ncbi.nlm.nih.gov/pubmed/26872887",
    "http://www.ncbi.nlm.nih.gov/pubmed/27895055",
    "http://www.ncbi.nlm.nih.gov/pubmed/26686866",
    "http://www.ncbi.nlm.nih.gov/pubmed/26519420",
    "http://www.ncbi.nlm.nih.gov/pubmed/25387210"
  ],
  "snippets": [
    {
      "text": "Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26449414",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab and andexanet alfa are NOAC-specific reversal agents designed to reverse dabigatran and factor Xa inhibitors accordingly.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26627486",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26686866",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Andexanet alfa is a specific reversal agent for Factor Xa inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26686866",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In ex vivo, animal, and volunteer human studies, andexanet alfa (AnXa) was able to dose-dependently reverse Factor Xa inhibition and restore thrombin generation for the duration of drug administration. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26686866",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Andexanet alfa is an antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor enoxaparin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26872887",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Andexanet alfa is a factor Xa (FXa) decoy that binds to direct and indirect FXa inhibitors. In Phase III trials in healthy volunteers, andexanet alfa reduced anti-FXa activity by more than 90%, reduced the concentration of unbound direct FXa inhibitor, and inhibited thrombin generation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27147456",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Andexanet alfa (r-Antidote, PRT064445; Portola Pharmaceuticals) is a truncated form of enzymatically inactive factor Xa, which binds and reverses the anticoagulant action of the factor Xa inhibitors (e.g.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25494843",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recent results from phase 3/4 studies demonstrate efficacy for an antidote to dabigatran (idarucizumab, a monoclonal antibody fragment with specificity for dabigatran) and an antidote to factor Xa inhibitors (andexanet alfa, a recombinant and inactive form of factor Xa that binds inhibitors).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27913536",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "176\u2003Andexanet Alfa: An Investigational Universal Antidote for Reversal of Anticoagulation of Factor Xa Inhibitors in Healthy Human Volunteers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399455",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Andexanet alfa is an antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor enoxaparin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26872887",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26449414",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Andexanet alfa (AnXa), a recombinant modified FXa, is an investigational specific antidote for FXa inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399455",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "With Idarucizumab and Andexanet Alfa, specific antidotes have been developed against both, direct thrombin inhibitors as well as direct Factor Xa inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26069913",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "With Idarucizumab and Andexanet Alfa, specific antidotes have been developed against both, direct thrombin inhibitors as well as direct Factor Xa inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26069913",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26559317",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Specific reversal agents are currently under development (idarucizumab for dabigatran, andexanet alfa for Xa inhibitors, and PER977 for both Xa- and thrombin inhibitors), which will facilitate clinical management of severe bleeding and emergency surgery",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25431993",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "With Idarucizumab and Andexanet Alfa, specific antidotes have been developed against both, direct thrombin inhibitors as well as direct Factor Xa inhibitors. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26069913",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Andexanet alfa (r-Antidote, PRT064445; Portola Pharmaceuticals) is a truncated form of enzymatically inactive factor Xa, which binds and reverses the anticoagulant action of the factor Xa inhibitors (e.g.: rivaroxaban, apixaban and edoxaban).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25494843",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Andexanet alfa (AnXa), a recombinant modified FXa, is an investigational specific antidote for FXa inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399455",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Andexanet alfa (PRT064445), a specific reversal agent against factor Xa inhibitors, showed a complete reversal of anticoagulant activity of apixaban and rivaroxaban within minutes after administration without adverse effects in two recently completed parallel phase III trials ANNEXA-A and ANNEXA-R respectively.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27082776",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "New antidotes are being explored, including a mouse monoclonal antibody to dabigatran; andexanet alfa, a potential universal factor Xa inhibitor reversal agent; and a synthetic small molecule (PER977) that may be effective for the reversal of factor Xa inhibitors and direct thrombin inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25516695",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26559317",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Currently, two potential reversal agents for oral direct factor Xa inhibitors (andexanet alfa and ciraparantag) are at various stages of clinical development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27895055",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "176\u2003Andexanet Alfa: An Investigational Universal Antidote for Reversal of Anticoagulation of Factor Xa Inhibitors in Healthy Human Volunteers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27399455",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Recent results from phase 3/4 studies demonstrate efficacy for an antidote to dabigatran (idarucizumab, a monoclonal antibody fragment with specificity for dabigatran) and an antidote to factor Xa inhibitors (andexanet alfa, a recombinant and inactive form of factor Xa that binds inhibitors).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27913536",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000925",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000931",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019774"
  ],
  "exact_answer": "Factor Xa, Xa"
}